Antibody-mediated regulation of cellular immunity and the inflammatory response

Trends in Immunology

Volumn 24, Issue 9, 2003, Pages 474-478

  Casadevall, Arturo ^a   Pirofski, Liise Anne ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; IMMUNOGLOBULIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; TOXIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; B LYMPHOCYTE; CELLULAR IMMUNITY; COMPLEMENT FIXATION; DRUG EFFICACY; GENE EXPRESSION; HOST PATHOGEN INTERACTION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREGULATION; INFECTION; INFECTION SENSITIVITY; INFLAMMATION; NONHUMAN; OPSONIZATION; REVIEW;

EID: 0042881087     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4906(03)00228-X     Document Type: Article

References (53)

1. Behring E.A., et al. Ueber das zustandekommen der diptherie-immunitä t und der tetanus-immunität bei thieren. Deutch Med. Woch. 49:1890;1113-1114.
2. Ochs H.D., et al. X-linked agammaglobulinemia. A clinical and molecular analysis. Medicine (Baltimore). 75:1996;287-299.
3. Glatman-Freedman A., et al. Serum therapy for tuberculosis revisited: a reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis. Clin. Microbiol. Rev. 11:1998;514-532.
4. Anderson C.F., et al. Biasing immune responses by directing antigen to macrophage Fcγ receptors. J. Immunol. 168:2002;3697-3701.
5. Yuan R., et al. T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice. Proc. Natl. Acad. Sci. U. S. A. 94:1997;2483-2488.
6. Garraud O., et al. Malaria-specific antibody subclasses in immune individuals: a key source of information for vaccine design. Trends Immunol. 24:2003;30-35.
7. Subramaniam K.S., et al. Qualitative change in antibody responses of human immunodeficiency virus-infected individuals to pneumococcal capsular polysaccharide vaccination associated with highly active antiretroviral therapy. J. Infect. Dis. 187:2003;758-768.
8. Pirofski L. Polysaccharides, mimotopes and vaccines for fungal and encapsulated pathogens. Trends Microbiol. 9:2001;445-451.
9. Dromer F., et al. Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect. Immun. 55:1987;749-752.
10. Han Y., et al. Antibody response that protects against disseminated candidiasis. Infect. Immun. 63:1995;2714-2719.
11. Edelson B.T., et al. Paradigm revisited: antibody provides resistance to Listeria infection. J. Immunol. 163:1999;4087-4090.
12. Teitelbaum R., et al. A monoclonal antibody recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc. Natl. Acad. Sci. U. S. A. 95:1998;15688-15693.
13. Vecchiarelli A., et al. Antibody-mediated effects against Cryptococcus neoformans: evidence for interdependency and collaboration between humoral and cellular immunity. Res. Immunol. 149:1998;321-333.
14. Feldmesser M., et al. Effect of serum IgG1 against murine pulmonary infection with Cryptococcus neoformans. J. Immunol. 158:1997;790-799.
15. Vecchiarelli A., et al. Specific antibody to Cryptococcus neoformans alters human leukocyte cytokine synthesis and promotes T cell proliferation. Infect. Immun. 66:1998;1244-1247.
16. Mozaffarian N., et al. Immune complexes increase nitric oxide production by interferon-γ-stimulated murine macrophage-like J774.16 cells. J. Leukoc. Biol. 57:1995;657-662.
17. Rivera J., et al. Antibody efficacy in murine pulmonary Cryptococcus neoformans infection: a role for nitric oxide. J. Immunol. 168:2002;3419-3427.
18. Beenhouwer D.O., et al. Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans. Infect. Immun. 69:2001;6445-6455.
19. Feldmesser M., et al. Antibody-mediated protection in murine Cryptococcus neoformans infection is associated with subtle pleotrophic effects on the cytokine and leukocyte response. Infect. Immun. 70:2002;1571-1580.
20. Culkin S.J., et al. A novel role for B cells in early protective immunity to an intracellular pathogen Franciscella tularensis strain LVS. J. Immunol. 158:1997;3277-3284.
21. Markham R.B., et al. The role of cytophilic IgG3 antibody in T cell-mediated resistance to infection with the extracellular bacterium Pseudomonas aeruginosa. J. Immunol. 146:1991;316-320.
22. Eis-Hubinger A.M., et al. Anti-glycoprotein b monoclonal antibody protects T cell-dependent mice against herpes simplex virus infection by inhibition of virus replication at the inoculated mucous membranes. J. Gen. Virol. 74:1993;379-385.
23. + cells in eliminating an established tumor. Eur. J. Immunol. 27:1997;374-382.
24. Winslow G.M., et al. Antibody-mediated elimination of the obligate intracellular bacterial pathogen Erhlichia chaffeensis during active infection. Infect. Immun. 68:2000;2187-2195.
25. Badell E., et al. Human malaria in immunocompromised mice: an in vivo model to study defense mechanisms against Plasmodium falciparum. J. Exp. Med. 192:2000;1653-1659.
26. Gigliotti F., et al. Passive intranasal monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia. Infect. Immun. 70:2002;1069-1074.
27. Marinets A., et al. Protection against invasive amebiasis by a single monoclonal antibody directed against a lipophosphoglycan antigen localized on the surface of Entamoeba histolytica. J. Exp. Med. 186:1997;1557-1565.
28. Vossen A.C.T.M., et al. Fc receptor binding of anti-CD3 monoclonal antibodies is not essential for immunosuppression but triggers cytokine-related side effects. Eur. J. Immunol. 25:1995;1492-1496.
29. Marsh C.B., et al. Fc-γ receptor cross-linking induces peripheral blood mononuclear cell monocyte chemoattractant protein-1 expression. J. Immunol. 158:1997;1078-1084.
30. Marsh C.B., et al. Monocyte Fc-γ receptor cross-linking induces IL-8 production. J. Immunol. 155:1995;3161-3167.
31. Tripp C.S., et al. Immune complexes inhibit antimicrobial responses through interleukin-10 production. J. Clin. Invest. 95:1995;1628-1694.
32. Hogarth P.M. Fc receptors are major mediators of antibody based inflammation in autoimmunity. Curr. Opin. Immunol. 14:2002;798-802.
33. Gerber J.S., et al. Stimulatory and inhibitory signals originating from the macrophage Fcγ receptors. Microbes Infect. 3:2001;131-139.
34. Redegeld F.A., et al. Immunoglobulin free light chains and mast cells: pivotal role in T-cell-mediated immune reactions? Trends Immunol. 24:2003;181-185.
35. Diamond M.S., et al. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J. Virol. 77:2003;2578-2586.
36. Buendia A.J., et al. B-cell-deficient mice show an exacerbated inflammatory response in a model of Chlamydophila abortus infection. Infect. Immun. 70:2002;6911-6918.
37. Smelt S.C., et al. B cell-deficient mice are highly resistant to Leishmania donovani infection, but develop neutrophil-mediated tissue pathology. J. Immunol. 164:2000;3681-3688.
38. Kang H., et al. Decreased resistance of B cell-deficient mice to infection with Toxoplasma gondii despite unimpaired expression of IFN-γ, TNF-α, and inducible nitric oxide synthase. J. Immunol. 164:2000;2629-2634.
39. Deshpande S.P., et al. Pathogenesis of herpes simplex virus-induced ocular immunoinflammatory lesions in B-cell-deficient mice. J. Virol. 74:2000;3517-3524.
40. Wright K.E., et al. Antiviral antibodies attenuate T-cell-mediated immunopathology following acute lymphocytic choriomeningitis virus infection. J. Virol. 65:2003;3001-3006.
41. Boes M., et al. Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc. Natl. Acad. Sci. U. S. A. 97:2000;1184-1189.
42. + T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in mice. J. Gen. Virol. 82:2001;845-853.
43. Dickler H.B., et al. Current perspectives on the use of intravenous immunoglobulin. Adv. Intern. Med. 41:1997;641-680.
44. Konishi E., et al. Naturally occurring immunoglobulin M antibodies: enhancement of phagocytic and microbicidal activities of human neutrophils against Toxoplasma gondii. Parasitology. 104:1992;427-432.
45. Dominguez M., et al. Complement interaction with trypanosomatid promastigotes in normal human serum. J. Exp. Med. 195:2002;451-459.
46. Schlesinger L.S., et al. A role for natural antibody in the pathogenesis of leprosy: antibody in nonimmune serum mediates C3 fixation to the Mycobacterium leprae surface and hence phagocytosis by human mononuclear phagocytes. Infect. Immun. 62:1994;280-289.
47. Robbins J.B., et al. Perspective: Hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J. Infect. Dis. 171:1995;1387-1398.
48. Rhodes S.G., et al. Is 'timing' important for cytokine polarization? Trends Immunol. 23:2002;246-249.
49. Mukherjee J., et al. Protective and non-protective monoclonal antibodies to Cryptococcus neoformans originating from one B-cell. J. Exp. Med. 181:1995;405-409.
50. Taborda C.P., et al. More is not necessarily better: 'prozone-like' effects in passive immunization with immunoglobulin G. J. Immunol. 170:2003;3621-3630.
51. Nussbaum G., et al. Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy. J. Exp. Med. 185:1997;685-697.
52. Chang Q., et al. Structure-function relationships for human antibodies to pneumococcal capsular polysaccharide from transgenic mice with human immunoglobulin Loci. Infect. Immun. 70:2002;4977-4986.
53. Casadevall A., et al. Host-pathogen interactions: redefining the basic concepts of virulence and pathogenicity. Infect. Immun. 67:1999;3703-3713.